Pharmaceutical

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 

Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.

Sep 8, 2024 - 04:00
Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 
Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.
Read the original article

Tags:

Previous Article

Onward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to advan...

Next Article

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Nurses and health care support workers at higher risk of suicide, study finds

Nurses and health care support workers at higher risk o...

Sep 26, 2023

How pharmaceutical firms are making their supply chains more efficient

How pharmaceutical firms are making their supply chains...

May 6, 2023

Johnson & Johnson bets heavy on AI-driven drug discovery

Johnson & Johnson bets heavy on AI-driven drug discovery

Dec 1, 2023